Terumo Medical Corporation has welcomed the publication of updated guidelines from the American College of Cardiology (ACC), American Heart Association (AHA) and the Society for Cardiovascular Angiography and Interventions (SCAI) which upgrade the recommendation for radial access in patients undergoing percutaneous coronary intervention (PCI).
Published in December 2021, the joint guidelines for coronary artery revascularisation give radial access a class 1 (Level of Evidence A) indication for PCI for both acute coronary syndrome (ACS) and stable ischemic heart disease (SIHD). With the updated guidelines, it is expected that more physicians will expand their use of radial access.
“As the first company to design and manufacture products specifically for radial access, Terumo has been a leader in supporting the important shift to the ‘radial first’ approach to interventional cardiology,” said Michael Martinelli, Terumo’s chief medical officer. “Our strategy, our product portfolio, our support for clinical trials, and especially our educational outreach to healthcare providers have provided an essential platform for the growth and success of radial access for coronary intervention and as such contributed significantly to improved outcomes for millions of patients worldwide.”
“The decision of the ACC, AHA and SCAI to recognise radial access with this level of clinical evidence will lead to improved patient outcomes, which is our primary goal as a company and an industry,” added Chris Pearson, executive vice president, Commercial Operations, Terumo Interventional Systems—North America. “We at Terumo are proud to have played a significant role in bringing radial access to the forefront of clinical practice.”
